TL;DR
Researchers have identified a potential blood-based biomarker—the ratio of VEGF to CITED2 proteins—that predicts how well a stroke patient's brain can reroute blood flow through backup vessels. A higher ratio in peripheral blood cells strongly correlates with "good" collateral circulation, offering a non-invasive way to assess a patient's prognosis and potential for recovery.
What Problem Does This Paper Address?
When an acute ischemic stroke (AIS) occurs, a blood vessel in the brain is blocked. The immediate area of the blockage dies quickly, but the surrounding tissue—known as the penumbra—can often be saved if blood can reach it through alternative routes. These "backup" routes are called collateral circulation.
The quality of a patient's collateral circulation is a primary driver of their clinical outcome. Currently, doctors evaluate these vessels using expensive and sometimes invasive imaging techniques like CT Angiography (CTA) or Digital Subtraction Angiography (DSA). There is a significant clinical need for a simple, sensitive blood-based biomarker that can predict collateral status without requiring specialized imaging suites or contrast agents.
Methods
The researchers conducted an observational study of 67 AIS patients. To determine the "ground truth" of their collateral circulation, they used DWI-ASPECTS, an MRI-based scoring system where a score >7 indicates "good" collateral flow and $\le$7 indicates "poor" flow.
The novel part of their approach involves looking at Peripheral Blood Mononuclear Cells (PBMCs). They isolated these cells from patient blood samples and used Western Blotting to quantify the expression of two specific proteins:
- VEGF (Vascular Endothelial Growth Factor): A well-known protein that promotes the growth of new blood vessels (angiogenesis).
- CITED2: A regulatory protein that acts as a "molecular switch." It competes with other factors to inhibit the expression of VEGF under hypoxic (low oxygen) conditions.
By calculating the VEGF/CITED2 ratio, the team aimed to capture the balance between pro-angiogenic signaling and its natural inhibitors.
Datasets
The study utilized a primary clinical dataset of 67 patients diagnosed with AIS at Zhujiang Hospital, China, between November 2020 and November 2021.
- Good Collateral Group: 46 patients.
- Poor Collateral Group: 21 patients. The trial is registered at ClinicalTrials.gov (identifier: NCT05345366). No external benchmark datasets were used, as this is a primary clinical validation study.
Key Insights and Ideas
- The Power of the Ratio: Interestingly, neither VEGF nor CITED2 levels were statistically significant predictors of collateral circulation when looked at individually. However, the ratio between them was highly significant. This suggests that the biological "tug-of-war" between growth factors and their regulators is more informative than absolute protein concentrations.
- PBMCs as Biological Proxies: The study reinforces the idea that circulating blood cells (PBMCs) reflect the systemic response to a brain injury. These cells are recruited to the ischemic site, and their internal protein expression mirrors the body's attempt to repair or bypass the damage.
- A Molecular Switch: The paper highlights CITED2's role in the HIF-1$\alpha$ pathway. In "good" collateral environments, the inhibitory effect of CITED2 is likely weaker, allowing VEGF to drive the establishment of backup vessels.
Key Results
- Predictive Accuracy: The Area Under the Curve (AUC) for the VEGF/CITED2 ratio was 0.861, indicating high diagnostic accuracy.
- Optimal Threshold: The researchers identified an optimal cutoff value of 1.013.
- Patients with a ratio > 1.013 were significantly more likely to have good collateral circulation.
- This threshold yielded a sensitivity of 89.1% and a specificity of 85.7%.
- Independent Factor: After adjusting for confounding variables (like age, smoking, and other blood counts) in a multivariate logistic regression, the VEGF/CITED2 ratio remained an independent protective factor (Odds Ratio: 165.79).
Limitations and Future Work
The authors acknowledge several hurdles before this can reach the clinic:
- Sample Size: With only 67 patients from a single center, the findings need validation in much larger, multi-center cohorts.
- Indirect "Gold Standard": The study used DWI-ASPECTS (MRI) as the reference for collateral circulation. While common, it is less precise than Digital Subtraction Angiography (DSA), the true gold standard.
- Temporal Dynamics: Blood was collected within 24 hours of hospitalization. It is unclear how this ratio fluctuates over the days following a stroke or if it can predict long-term vascular remodeling.
- Practicality: Western Blotting is a labor-intensive laboratory technique. For this to be a rapid clinical tool, the assay would likely need to be converted into a faster format, such as an ELISA or a point-of-care test.
Summary updated